Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.

Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R.

Med Oncol. 2010 Sep;27(3):899-906. doi: 10.1007/s12032-009-9303-z. Epub 2009 Sep 12.

PMID:
19757215
2.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.

J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18.

PMID:
19451442
3.

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

Larkin JM, Ferguson TR, Pickering LM, Edmonds K, James MG, Thomas K, Banerji U, Berns B, de Boer C, Gore ME.

Br J Cancer. 2010 Oct 12;103(8):1149-53. doi: 10.1038/sj.bjc.6605889. Epub 2010 Sep 14.

4.

Sorafenib for the treatment of advanced renal cell carcinoma.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.

Clin Cancer Res. 2006 Dec 15;12(24):7271-8. Review.

5.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.

J Clin Oncol. 2006 Jun 1;24(16):2505-12. Epub 2006 Apr 24.

PMID:
16636341
6.

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.

J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16.

PMID:
21576636
7.

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN.

BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x.

8.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
9.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.

J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288.

PMID:
18445842
10.

Sorafenib: in advanced renal cancer.

McKeage K, Wagstaff AJ.

Drugs. 2007;67(3):475-83; discussion 484-5. Review.

PMID:
17335301
11.

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.

Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S.

Jpn J Clin Oncol. 2007 Oct;37(10):755-62. Epub 2007 Oct 19.

PMID:
17951335
12.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

13.

Sorafenib in advanced hepatocellular carcinoma.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group.

N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.

14.

Sorafenib: in hepatocellular carcinoma.

Simpson D, Keating GM.

Drugs. 2008;68(2):251-8. Review.

PMID:
18197728
15.

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.

Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE.

J Clin Oncol. 2010 Feb 20;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19.

PMID:
20085939
16.

Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

Hutson TE.

Expert Rev Anticancer Ther. 2007 Sep;7(9):1193-202. Review.

PMID:
17892420
17.

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B; Sorafenib TARGET Clinical Trial Group.

Eur J Cancer. 2010 Sep;46(13):2432-40. doi: 10.1016/j.ejca.2010.06.121. Epub 2010 Jul 23.

PMID:
20656473
18.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.

Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8.

19.

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.

Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H.

BJU Int. 2011 Dec;108(11):1813-9. doi: 10.1111/j.1464-410X.2011.10281.x. Epub 2011 Apr 11.

20.

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Autier J, Escudier B, Wechsler J, Spatz A, Robert C.

Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.

PMID:
18645140

Supplemental Content

Support Center